See more : Cavalier Resources Limited (CVR.AX) Income Statement Analysis – Financial Results
Complete financial analysis of Timber Pharmaceuticals, Inc. (TMBR) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Timber Pharmaceuticals, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Verde Bio Holdings, Inc. (VBHI) Income Statement Analysis – Financial Results
- Meiho Holdings,Inc. (7369.T) Income Statement Analysis – Financial Results
- HIMALAYA FOOD INTERNATIONAL LI (HFIL.BO) Income Statement Analysis – Financial Results
- Citigroup Inc. (TRVC.DE) Income Statement Analysis – Financial Results
- Enphys Acquisition Corp. (NFYS) Income Statement Analysis – Financial Results
Timber Pharmaceuticals, Inc. (TMBR)
About Timber Pharmaceuticals, Inc.
Timber Pharmaceuticals LLC, a clinical-stage biopharmaceutical company, engages in the development and commercialization of treatments for orphan dermatologic diseases. The company's lead product candidates include TMB-001, a patented topical formulation of isotretinoin that has completed Phase 2b clinical trial for the treatment of moderate to severe subtypes of CI, a group of rare genetic keratinization disorders; and TMB-002, a proprietary topical formulation of rapamycin, which is in Phase 2b clinical trial for the treatment of facial angiofibroma in tuberous sclerosis complex, a multisystem genetic disorder resulting in the growth of hamartomas in multiple organs. It is also involved in the development of TMB-003, a proprietary formulation of Sitaxsentan, which is a selective endothelin-A receptor antagonist that is in preclinical development for the treatment of sclerotic skin diseases. In addition, the company engages in the development of BPX-01, which is in Phase 3 topical minocycline for the treatment of inflammatory lesions of acne vulgaris; and BPX-04 that is a Phase 3 ready topical minocycline for the treatment of papulopustular rosacea. It has license agreement with AFT Pharmaceuticals Limited. The company was founded in 2019 and is headquartered in Basking Ridge, New Jersey.
| Metric | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 83.18K | 295.74K | 453.81K | 324.65K | 57.00K | 73.00K | 100.00K | 64.00K | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 13.30M | 6.15M | 1.50M | 3.38M | 83.00K | 250.00K | 516.00K | 237.00K | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -13.22M | -5.85M | -1.05M | -3.06M | -26.00K | -177.00K | -416.00K | -173.00K | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | -15,892.35% | -1,979.40% | -230.78% | -941.95% | -45.61% | -242.47% | -416.00% | -270.31% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 13.30M | 6.15M | 15.10M | 3.38M | 9.08M | 9.14M | 10.16M | 5.70M | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 5.24M | 5.14M | 4.65M | 4.17M | 0.00 | 52.31K | 27.96K | 59.11K |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 2.16M | 2.42M | 3.20M | 5.11M | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 6.02M | 5.39M | 4.06M | 586.56K | 7.40M | 7.56M | 7.85M | 9.28M | 0.00 | 52.31K | 27.96K | 59.11K |
| Other Expenses | -83.18K | -590.79K | -453.81K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 19.24M | 10.95M | 18.71M | 586.72K | 16.48M | 16.70M | 18.01M | 14.99M | 0.00 | 52.31K | 27.96K | 59.11K |
| Cost & Expenses | 19.24M | 10.95M | 18.71M | 3.97M | 16.56M | 16.95M | 18.53M | 15.22M | 0.00 | 52.31K | 27.96K | 59.11K |
| Interest Income | 2.45K | 15.55K | 816.66K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.00 | 2.00 | 0.00 |
| Interest Expense | 228.46K | 15.55K | 4.42M | 0.00 | 28.00K | 364.00K | 163.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 77.45K | 272.88K | 2.43M | 171.86K | 62.00K | 52.00K | 260.00K | 86.00K | 0.00 | 0.00 | 0.00 | 0.00 |
| EBITDA | -19.16M | -10.38M | -17.78M | -45.56K | -17.17M | -16.88M | -17.98M | -15.16M | 0.00 | -52.31K | -27.96K | -59.11K |
| EBITDA Ratio | -23,032.75% | -3,601.23% | -3,917.31% | -14.03% | -30,115.79% | -32,717.81% | -17,981.00% | -24,231.25% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -19.24M | -10.65M | -20.21M | -3.64M | -17.23M | -23.94M | -18.24M | -15.59M | 0.00 | -52.31K | -27.96K | -59.11K |
| Operating Income Ratio | -23,125.86% | -3,601.23% | -4,453.82% | -1,122.63% | -30,224.56% | -32,789.04% | -18,241.00% | -24,365.63% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -136.45K | -19.17K | 5.13M | -156.00 | -750.00K | 238.00K | -163.00K | -436.00K | 0.00 | 1.00 | 2.00 | 0.00 |
| Income Before Tax | -19.37M | -10.67M | -15.08M | -3.64M | -17.26M | -16.64M | -18.40M | -15.59M | 0.00 | -52.30K | -27.96K | -59.11K |
| Income Before Tax Ratio | -23,289.91% | -3,607.72% | -3,322.93% | -1,122.68% | -30,273.68% | -22,791.78% | -18,404.00% | -24,365.63% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 7.60K | -30.24K | 37.84K | -156.00 | 2.00K | -7.66M | 2.00K | 4.00K | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income | -19.38M | -10.64M | -15.12M | -3.69M | -17.26M | -8.98M | -18.41M | -15.60M | 0.00 | -52.30K | -27.96K | -59.11K |
| Net Income Ratio | -23,299.05% | -3,597.49% | -3,331.27% | -1,136.66% | -30,277.19% | -12,298.63% | -18,406.00% | -24,371.88% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -9.19 | -13.15 | -48.15 | -29.31 | -1.34K | -1.57K | -7.71K | -13.03K | 0.00 | -0.01 | 0.00 | -0.01 |
| EPS Diluted | -9.19 | -13.15 | -48.15 | -29.31 | -1.34K | -1.57K | -7.71K | -13.03K | 0.00 | -0.01 | 0.00 | -0.01 |
| Weighted Avg Shares Out | 2.11M | 808.81K | 314.00K | 125.91K | 12.88K | 5.73K | 2.39K | 1.20K | 204.34K | 9.00M | 9.00M | 8.21M |
| Weighted Avg Shares Out (Dil) | 2.11M | 808.81K | 314.00K | 125.91K | 12.88K | 5.73K | 2.39K | 1.20K | 204.34K | 9.00M | 9.00M | 8.21M |
Timber Pharmaceuticals, Inc., a LEO Pharma Company, Presents Late-Breaking Preliminary Results of TMB-001 in Moderate-to-Severe Congenital Ichthyosis (CI) at the 2024 AAD Annual Meeting
LEO Pharma Finalizes Acquisition of Key Assets From Timber Pharmaceuticals
Timber Pharmaceuticals Announces Commencement of NYSE American Delisting Proceedings: Common Stock Expected to Begin Trading on the OTC Market
Timber Pharmaceuticals Announces Commencement of NYSE American Delisting Proceedings: Common Stock Expected to Begin Trading on the OTC Market
Timber Pharmaceuticals Receives Court Approval of All “First Day” Motions to Support Business Operations & Discloses Communication From NYSE American
NYSE American to Commence Delisting Proceedings Against Timber Pharmaceuticals, Inc. (TMBR)
Timber Pharmaceuticals Announces NYSE Acceptance of Plan to Regain Listing Compliance
TIMBER PHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Timber Pharmaceuticals, Inc. - TMBR
Timber (TMBR) to Get Acquired by LEO Pharma for $36M, Stock Up
TMBR Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Timber Pharmaceuticals, Inc. Is Fair to Shareholders
Source: https://incomestatements.info
Category: Stock Reports